This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
4
0
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: LQDA).
While the company’s franchise position within the “highly attractive” pulmonary arterial hypertension (PAH) market is unique, its key growth asset faces significant competition, according to Goldman Sachs.
The United Therapeutics Analyst: Chris Shibutani upgraded the rating for United Therapeutics from Sell to Neutral, while raising the price target from $213 to $215.
The United Therapeutics Thesis: The company’s Tyvaso will face headwinds from the anticipated entry of Merck & Co Inc’s …
Full story available on Benzinga.com
Visited 4 times, 1 visit(s) today